文献速递胸部肿瘤骨软组织肉瘤与黑色素瘤支持与姑息治疗

他泽司他(EZH2抑制剂)治疗复发或难治性B细胞非霍奇金淋巴瘤及晚期实体瘤:首次人体、开放标签、1期研究

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
PubMed 文献 · Lancet Oncol · 2018-04-09

这项首次人体1期研究在64例复发或难治性B细胞非霍奇金淋巴瘤(21例)或晚期实体瘤(43例)患者中评估EZH2抑制剂他泽司他的安全性、临床活性、药代动力学和药效动力学。推荐2期剂量为800 mg每日两次;B细胞非霍奇金淋巴瘤客观缓解率38%,实体瘤5%。

要点

  • 他泽司他推荐2期剂量为800 mg每日两次口服。
  • B细胞非霍奇金淋巴瘤患者客观缓解率38%(8/21),实体瘤患者5%(2/43)。
  • 常见治疗相关不良事件为乏力、贫血、恶心等,多为1-2级。

核心结论

  • 他泽司他在难治性B细胞非霍奇金淋巴瘤和晚期实体瘤(包括上皮样肉瘤)中显示出良好的安全性和抗肿瘤活性。

研究设计与样本

  • 开放标签、多中心、剂量递增1期研究,采用3+3设计,在法国两个中心进行。
  • 纳入64例复发或难治性B细胞非霍奇金淋巴瘤(21例)或晚期实体瘤(43例)患者,年龄>18岁,ECOG体力状态0或1。
  • 他泽司他口服给药,剂量从100 mg每日两次至1600 mg每日两次,28天为一个周期。

主要发现

  • 最常见的治疗相关不良事件为乏力(21/64,33%)、贫血(9/64,14%)、食欲减退(4/64,6%)、肌肉痉挛(9/64,14%)、恶心(13/64,20%)和呕吐(6/64,9%),通常为1或2级。
  • 在最高剂量1600 mg每日两次时出现1例剂量限制性毒性:4级血小板减少。
  • 无治疗相关死亡;7例(11%)患者发生非治疗相关死亡(200 mg每日两次组1例,400 mg每日两次组4例,1600 mg每日两次组2例)。
  • B细胞非霍奇金淋巴瘤患者中8例(38%,8/21)观察到持久客观缓解,包括完全缓解;实体瘤患者中2例(5%,2/43)观察到客观缓解。

关键数值与推荐

  • 推荐2期剂量确定为800 mg每日两次。

临床怎么用

  • 他泽司他可用于复发或难治性B细胞非霍奇金淋巴瘤及晚期实体瘤(包括上皮样肉瘤)的进一步临床研究。
  • 正在进行的2期成人研究和1期儿童研究正在招募B细胞非霍奇金淋巴瘤和INI1阴性或SMARCA4阴性肿瘤患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Activating enhancer of zeste homolog 2 (EZH2) mutations or aberrations of the switch/sucrose non-fermentable (SWI/SNF) complex (eg, mutations or deletions of the subunits INI1 or SMARCA4) can lead to aberrant histone methylation, oncogenic transformation, and a proliferative dependency on EZH2 activity. In this first-in-human study, we aimed to investigate the safety, clinical activity, pharmacokinetics, and pharmacodynamics of tazemetostat, a first-in-class selective inhibitor of EZH2. METHODS: We did an open-label, multicentre, dose-escalation, phase 1 study using a 3 + 3 design with planned cohort expansion at the two highest doses below the maximally tolerated dose. The study was done at two centres in France: Institut Gustave Roussy (Villejuif, Val de Marne) and Institut Bergonié (Bordeaux, Gironde). Eligible patients had relapsed or refractory B-cell non-Hodgkin lymphoma or an advanced solid tumour and were older than 18 years, with Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate end-organ function. Tazemetostat was administered orally from 100 mg twice daily to 1600 mg twice daily in 28-day cycles. The primary endpoint was to establish the maximum tolerated dose or recommended phase 2 dose of tazemetostat, as determined by dose-limiting toxicities, laboratory values, and other safety or pharmacokinetic measures in cycle one according to local investigator assessment. Safety was assessed in patients who received at least one dose of tazemetostat; antitumour activity was assessed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01897571. The phase 1 part of the study is complete, and phase 2 is ongoing. FINDINGS: Between June 13, 2013, and Sept 21, 2016, 64 patients (21 with B-cell non-Hodgkin lymphoma, and 43 with advanced solid tumours) received doses of tazemetostat. The most common treatment-related adverse events, regardless of attribution, were asthenia (21 [33%] of 64 treatment-related events), anaemia (nine [14%]), anorexia (four [6%]), muscle spasms (nine [14%]), nausea (13 [20%]), and vomiting (six [9%]), usually grade 1 or 2 in severity. A single dose-limiting toxicity of grade 4 thrombocytopenia was identified at the highest dose of 1600 mg twice daily. No treatment-related deaths occurred; seven (11%) patients had non-treatment-related deaths (one at 200 mg twice daily, four at 400 mg twice daily, and two at 1600 mg twice daily). The recommended phase 2 dose was determined to be 800 mg twice daily. Durable objective responses, including complete responses, were observed in eight (38%) of 21 patients with B-cell non-Hodgkin lymphoma and two (5%) of 43 patients with solid tumours. INTERPRETATION: Tazemetostat showed a favourable safety profile and antitumour activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumours, including epithelioid sarcoma. Further clinical investigation of tazemetostat monotherapy is ongoing in phase 2 studies in adults and a phase 1 study for children, which are currently enrolling patients who have B-cell non-Hodgkin lymphoma and INI1-negative or SMARCA4-negative tumours. FUNDING: Epizyme and Eisai.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Italiano A, Soria JC, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018. PMID: 29650362. doi:10.1016/S1470-2045(18)30145-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。